Aethlon Medical, Inc. (NASDAQ:AEMD) saw some unusual options trading on Wednesday. Stock traders acquired 9,398 call options on the stock. This represents an increase of approximately 2,399% compared to the typical daily volume of 376 call options.
A number of equities research analysts recently weighed in on AEMD shares. Maxim Group reaffirmed a “buy” rating and set a $11.00 price objective on shares of Aethlon Medical in a research report on Friday, June 25th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Aethlon Medical in a research note on Tuesday, August 10th.
A number of institutional investors have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in shares of Aethlon Medical during the first quarter worth about $40,000. Millennium Management LLC acquired a new position in Aethlon Medical in the first quarter valued at approximately $30,000. Citadel Advisors LLC acquired a new position in Aethlon Medical in the first quarter valued at approximately $29,000. State Street Corp acquired a new position in shares of Aethlon Medical during the second quarter worth approximately $96,000. Finally, Geode Capital Management LLC boosted its position in shares of Aethlon Medical by 54.5% during the second quarter. Geode Capital Management LLC now owns 103,121 shares of the medical equipment provider’s stock worth $507,000 after buying an additional 36,368 shares during the period. Hedge funds and other institutional investors own 5.53% of the company’s stock.
Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Sunday, August 8th. The medical equipment provider reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). On average, equities research analysts expect that Aethlon Medical will post -0.62 earnings per share for the current fiscal year.
Aethlon Medical Company Profile
Aethlon Medical, Inc is a medical technology company, which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI.
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.